Novocure’s Optune Now Available at More Than 600 Cancer Treatment Centers in the U.S.

IN.PACT AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors.

ESPRIT CAM Improves Productivity for Long Part Machining by Automating Multi-spindle Program Creation

ESPRIT CAM: New computer-aided-manufacturing (CAM) technology has been introduced by ESPRIT CAM, part of Hexagon’s Manufacturing Intelligence division that provides manufacturers with the control and flexibility needed to use multi-spindle and multi-channel computer-numerical-control (CNC) machinery for the machining of long parts.

Novocure™ (NASDAQ: NVCR) announced today that physicians at more than 600 cancer treatment centers in the U.S. have been certified to prescribe Optune to newly diagnosed and recurrent glioblastoma (GBM) patients.

Optune is Novocure’s wearable, portable, FDA-approved Tumor Treating Fields (TTFields) delivery system for the treatment of GBM. Physicians at an additional 350 medical institutions throughout the world also can prescribe Optune to GBM patients.

“We are proud to have certified physicians at a variety of cancer treatment centers, both large and small, in the community and academic settings, nationally and worldwide,” said Novocure’s CEO Asaf Danzinger. “It is our goal to bring our therapy to all GBM patients who can benefit from it. Optune is now more accessible to GBM patients than ever before, and we remain focused on broadening its reach.”

The latest physician certifications broaden the geographic reach of Optune in the community setting, making the therapy more accessible to patients.

Dr. Joseph C. Hodges, a radiation oncologist and certified Optune prescriber at Texas Oncology in Longview, Texas. said, “As a pioneer of community-based oncology, we strive to enhance patient access to innovative cancer treatments so patients can stay connected to the support of their families, friends and community during the challenging time of a cancer diagnosis.” Optune provides immense benefit to GBM patients, and we are excited to now offer this treatment to our patients,” concluded Hodges.

spot_img

DON'T MISS

Related Articles